NCT05561491View on ClinicalTrials.gov

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Melanoma
Interventions
BIOLOGICAL

ONCOS-102

Oncolytic virus

BIOLOGICAL

Balstilimab

Anti PD-1

Sponsors

Collaborators (1)

Agenus Inc.
All Listed Sponsors
collaborator

Agenus Inc.

INDUSTRY

lead

Targovax Oy

INDUSTRY

NCT05561491 - A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients | Biotech Hunter | Biotech Hunter